OSLO, Norway, Oct. 12, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaboratorswill present data and analyses from its non-clinical and clinical studies with Betalutin® (177Lu-lilotomab satetraxetan) at the 32nd Annual Congress of the European Association of Nuclear Medicine (13-17 October 2018, Düsseldorf,
The presentations are:
Therapeutic efficacy of 177Lu-lilotomab satetraxetan in non-Hodgkin B-cell Lymphoma is controlled by G2/M cell cycle progression
Authors: A. Pichard et al. Session: 305 - M2M: Therapy Effects, PreclinicalAbstract No. OP-069 Format: Oral presentation
Date/time: Sunday 14 October, 11:30-12:45 CEST
Tumor Absorbed Dose and Changes in FDG PET Parameters in Non-Hodgkin Lymphoma Patients Treated with 177Lu-lilotomab satetraxetan
Authors: A. Løndalen et al.Session: 608 - Clinical Oncology - Rapid Fire Session: It´s in the Blood! Abstract No. OP-252 Format: Oral presentation
Date/time: Monday 15 October, 08:00-09:30 CEST
Abstracts are available by clicking here clicking here
For further information, please contact:
Malene BrondbergVP Investor Relations and Corporate Communications Cell: +44-7561-431-762 Email: email@example.com
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson) Tel: +44-207-638-9571 Email: firstname.lastname@example.org
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-presentations-at-the-annual-congress-of-the-european-association-of-nuclear-medicine-eanm-300730074.html
SOURCE Nordic Nanovector
Subscribe to our Free Newsletters!
A lump in the armpit can be due to a benign infection, allergy or fatty tissue growth. It is ...
Fennel seeds are a must-have in almost every Indian kitchen due to its health quotient. Here are a ...
True vertigo is a severe form of dizziness that is a movement hallucination. Try out some of these ...View All